1. EMPA-REG OUTCOME: The Endocrinologist's Point of View
Leigh Perreault, MD 
American Journal of Cardiology 
Volume 120, Issue 1, Pages S48-S52 (July 2017)
DOI: /j.amjcard
Copyright © 2017 The Author Terms and Conditions

2. Figure 1
Schematic representation of the potential metabolic and hemodynamic pathways responsible for the reduction in mortality and hospitalization for heart failure observed with empagliflozin in EMPA-REG OUTCOME.19 American Diabetes Association “SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.” American Diabetes Association, 2016 Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. Ang 1-7 = angiotensin 1-7; AT2 = angiotensin 2 receptor; ECFV = extracellular fluid volume; FFA = free fatty acids.
American Journal of Cardiology  , S48-S52DOI: ( /j.amjcard )
Copyright © 2017 The Author Terms and Conditions